Vivos Therapeutics shares are trading higher after Ascendiant Capital maintained a Buy rating on the stock and raised its price target from $6.4 to $6.6.
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics shares rose following Ascendiant Capital's decision to maintain a Buy rating and increase the price target from $6.4 to $6.6.
August 20, 2024 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vivos Therapeutics shares are trading higher after Ascendiant Capital maintained a Buy rating and raised its price target from $6.4 to $6.6.
The increase in price target and maintained Buy rating by Ascendiant Capital is a positive signal to investors, likely boosting short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100